Thermo Fisher Scientific

• 10-QQ2 FY2026PositiveRestructuring

  Filed Jul 31

  Clario boosted clinical research as acquisitions outpaced organic growth; deal spending and buybacks raised debt.

  • Revenue$12.0BYoY +10.5%
  • Net income$1.7BYoY +7.4%

• 8-KPositiveEarningsGuidance deferred to the call

  Filed Jul 23

  Strengthening customer activity supports organic growth; microbiology business divestiture announced.

• 8-KShareholder vote

  Filed May 26

  Shareholders rejected executive compensation in the advisory say-on-pay vote, while electing all director nominees.

• 10-QQ1 FY2026Restructuring

  Filed May 1

  Clario expands clinical research but adds debt; acquisitions and currency drove most revenue growth.

  • Revenue$11.0BYoY +6.2%
  • Net income$1.7BYoY +9.6%

• 8-KPositiveEarningsGuidance deferred to the call

  Filed Apr 23

  Acquisitions and currency drove most revenue growth; the Clario acquisition closed.

• 8-KPositiveDeal completed

  Filed Mar 24

  Clario acquisition closes, adding clinical-trial endpoint data capabilities to Laboratory Products and Biopharma Services.

• 10-KFY2025Restructuring

  Filed Feb 26

  Bioproduction and pharma services drove growth despite weak China and instruments; Solventum filtration and planned Clario deals expand drug-workflow exposure.

  • Revenue$44.6BYoY +3.9%
  • Net income$6.7BYoY +5.8%

• 8-KDebt financing

  Filed Feb 12

  Senior notes issued to fund part of the pending Clario acquisition’s cash consideration.

• 8-KPositiveEarningsGuidance deferred to the call

  Filed Jan 29

  M&A commitments totaled $13B in 2025; acquisitions and currency supplemented organic revenue growth.

• 8-KCEO/CFO changeLeadership change

  Filed Jan 12

  Lagarde and Lowery will leave to pursue other opportunities; Gianluca Pettiti becomes president and COO.

Coverage: 10-K filings filed since Feb 26, 2026; 10-Q since May 1, 2026; 8-K since Jan 12, 2026.

Request longer coverage

Company data: Wikidata Q643674